β受体阻滞剂暴露后银屑病风险:药物警戒信号描述
病例/非病例研究显示报告比值比为8.95(95%CI 7.75-10.33),提示存在统计学显著的不比例性,构成药物警戒信号。
要点
- β受体阻滞剂暴露后银屑病风险呈类效应,需关注用药后皮肤变化
- 报告比值比8.95(95%CI 7.75-10.33),存在统计学显著不比例性
- 建议在β受体阻滞剂暴露第一年内加强监测
核心结论
- β受体阻滞剂暴露与银屑病风险之间存在统计学显著的不比例性,构成药物警戒信号,且该风险为类效应。
- 建议在β受体阻滞剂暴露第一年内加强监测。
研究设计与样本
- 研究为回顾性、描述性分析,数据来源于法国国家药物警戒数据库(FPVD)1985至2019年的自发报告。
- 采用病例/非病例研究评估银屑病风险与β受体阻滞剂暴露之间的关联。
主要发现
- 涉及心脏选择性与非心脏选择性、局部与全身用β受体阻滞剂,主要用药指征为高血压。
- 平均起病时间为5个月,停药后68%的患者转归良好。
- 报告比值比(ROR)为8.95(95%置信区间7.75-10.33)。
临床怎么用
- 临床处方β受体阻滞剂时应关注患者皮肤银屑病样表现,尤其在用药第一年内加强监测。
- 对出现银屑病样皮损者应考虑评估β受体阻滞剂暴露史并及时处理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: We aimed to investigate French pharmacovigilance data. The objective was to characterize psoriatic conditions that occurred after beta-blocker (BB) exposure and bring to light a possible pharmacovigilance signal. METHODS: Spontaneous reports of psoriatic conditions recorded in the French National Pharmacovigilance Database (FPVD) between 1985 and 2019 were extracted. We performed a retrospective, descriptive analysis of reports linked to BB exposure. Association between psoriasis risk and BB exposure was assessed using a case/noncase study. RESULTS: Two hundred and twenty-five reports of psoriatic conditions after BB exposure were recorded in the FPVD during the study period. Both cardioselective and noncardioselective, topical and systemic BBs are involved. Therapeutic indication of BB was mainly hypertension. Mean time to onset was 5 months and outcome was favourable in 68% after BB discontinuation. These features were concordant with those of literature reports. The reporting odds ratio (ROR) was 8.95 (95% confidence interval 7.75-10.33). CONCLUSION: We highlighted a statistically significant disproportionality which constitutes a pharmacovigilance signal. Psoriasis risk with BBs is a class effect. Increasing surveillance during the first year of BB exposure is needed.
引用
- Azzouz B, De Guizelin A, Lambert A, et al. Psoriasis risk after beta-blocker exposure: Description of a pharmacovigilance signal. Br J Clin Pharmacol. 2022. PMID: 35352377. doi:10.1111/bcp.15330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。